Nakano Yoshiteru
   Department   School of Medicine  Neurosurgery, Clinical Medical Sciences
Article types case reports
Language English
Peer review Peer reviewed
Title Vessel wall magnetic resonance imaging findings and surgical treatment in nilotinib-associated cerebrovascular disease: A case report.
Journal Formal name:Molecular and clinical oncology
Abbreviation:Mol Clin Oncol
ISSN code:20499450/20499450
Volume, Issue, Page 10(2),239-243頁
Author and coauthor Suzuki Kohei, Yamamoto Junkoh, Kakeda Shingo, Takamatsu Seishiro, Miyaoka Ryo, Kitagawa Takehiro, Saito Takeshi, Nakano Yoshiteru, Nishizawa Shigeru
Publication date 2019/02
Summary Nilotinib, a second-generation tyrosine kinase inhibitor, is considered as one of the most effective drugs for the treatment of chronic myeloid leukemia (CML); however, the use of nilotinib has been reported to be associated with vascular adverse events, such as peripheral arterial occlusive disease and ischemic heart disease. Moreover, there are few reports on cerebral vascular disease associated with nilotinib use. We herein describe the case of a 55-year-old male patient with CML, who presented with cerebral infarction and severe cerebrovascular stenosis that developed during nilotinib treatment. The patient was diagnosed with cerebral infarction and severe stenosis of the intracranial arteries associated with nilotinib use. Vessel wall magnetic resonance imaging (VW-MRI) revealed diffuse concentric thickening of the vessel wall, unlike ordinary patterns of atherosclerosis. The patient underwent direct revascularization (superficial temporal artery to middle cerebral artery bypass) and was successfully treated without recurrence. Based on this rare case, VW-MRI may be used to detect the morphological changes of the intracranial arteries that are associated with nilotinib use. Moreover, surgical revascularization may improve the prognosis of nilotinib-associated cerebrovascular diseases, such as severe stenosis or occlusion of the main trunk of the cerebral arteries, that cause brain ischemia.
DOI 10.3892/mco.2018.1780
PMID 30680201